Yantai Dongcheng Pharmaceutical

What Yantai Dongcheng Pharmaceutical does

Yantai Dongcheng Pharmaceutical Group Co. Ltd. (烟台东诚药业集团股份有限公司; SZSE: 002675) is a publicly listed Chinese pharmaceutical group founded in 1998 in Yantai, Shandong Province, and operating through approximately 80 subsidiaries across four business segments: pharmaceutical raw materials (heparin sodium API and LMWH injections such as enoxaparin, dalteparin, nadroparin; chondroitin sulfate; cytochrome C; collagen; hyaluronic acid; glucosamine), finished formulations (tablets, capsules, granules, drop pills, lyophilized powder injections, pre-filled syringes for respiratory, digestive, dermatological, cardiovascular, and endocrine indications), nuclear/radiopharmaceuticals (18F-FDG, Tc-99m labeled imaging agents including the proprietary Yunke Tc-99m MDP injection, sodium fluoride [18F] injection, iodine-125 sealed seed sources, and carbon-14 urea capsules), and consumer health products (Jiabaolin joint supplements, Kafukaka heparin-sodium cosmetics, functional foods). Nuclear medicine is operated through 32 production centers including facilities in Nanjing, Chengdu, Shanghai, Muping/Yantai, and Jilin Changchun, deploying more than 100 medical cyclotrons and providing short-half-life radiotracers to nuclear medicine departments serving approximately 95% of China's population; 18F-FDG reportedly holds about 50% domestic market share. APIs are exported to 40+ countries under multiple international certifications (US USP, EU CEP, Japan PMDA, Korea MFDS, Brazil ANVISA), and the chondroitin sulfate franchise benefits from a Thailand-based Sino Siam Biotechnique production node.

The group's revenue model is primarily one-time product sale through four channels: B2B pharmaceutical distribution and government hospital procurement for APIs and formulations in China; direct hospital supply for radiopharmaceuticals through the production network; retail pharmacy distribution for finished preparations including national-insurance-listed products; and e-commerce plus retail for consumer health products. International APIs reach global pharmaceutical manufacturers via established trading partners. Pricing for institutional pharmaceutical products is set through Chinese government tendering and hospital procurement processes; pricing details for other channels are not publicly disclosed. Customers span hospital nuclear medicine departments, domestic and international pharmaceutical manufacturers, dietary supplement producers (chondroitin sulfate, protein powders), retail pharmacy chains, and individual consumers of health supplements and cosmetics.

The company has expanded primarily through inorganic moves: the 2018 acquisition of Nanjing An Dikepo (An Dikepo) brought the radiopharmaceutical network into the group, while the 2015-2016 acquisitions of Chengdu Yunke Pharmaceutical (radiopharma, originator of the Yunke injection) and Sino Siam Biotechnique (Thailand chondroitin) extended the IP and international manufacturing footprint, supplemented by the 2022 establishment of Yantai Xinkesida for radiopharma cold kits and the 2020 founding of Dingrui Health for consumer products. Chairman You Shouyi leads the group, which is recognized on the 2026 Chemical Pharma R&D Strength TOP100 and 2025 China Pharmaceutical R&D Comprehensive Strength TOP100 rankings and holds GMP, ISO 9001, USP, EU CEP, Japan PMDA, Korea MFDS, and Brazil ANVISA certifications across its API and radiopharma subsidiaries.

Name

Yantai Dongcheng Pharmaceutical

Legal name

烟台东诚药业集团股份有限公司

Website

https://dcb-group.com

Company type

Public

Founded year

1998

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Yantai Dongcheng Pharmaceutical is a Chinese listed pharma group (SZSE: 002675) operating APIs (heparin, chondroitin), finished formulations, a 32-center nuclear radiopharmaceutical network covering ~95% of China's population, and consumer health products across 40+ export countries.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

Keywords

• Heparin API manufacturing
• Radiopharmaceutical production
• Chondroitin sulfate processing
• Finished pharmaceutical formulations
• Nuclear medicine products

Headquarters

HQ city

Jinan

HQ country

China

HQ region

Asia

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Raw Materials (API): Heparin series, chondroitin sulfate series, cytochrome C, and other biochemical raw materials sold globally to pharmaceutical manufacturers and supplement producers
2. Finished Pharmaceutical Preparations: Tablets, capsules, injections, and other dosage forms sold through pharmaceutical distribution channels and hospital procurement systems
3. Nuclear Radiopharmaceuticals: Short-lived PET and SPECT radiopharmaceuticals distributed through hospital nuclear medicine departments and diagnostic imaging centers
4. Consumer Health Products: Dietary supplements (joint care, vitamins, omega-3), cosmetics containing heparin sodium, and functional foods sold through retail and e-commerce channels

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

Yantai Dongcheng Pharmaceutical manufactures and sells pharmaceutical products across four business segments: (1) raw material medicines including heparin sodium API, chondroitin sulfate, cytochrome C, and glucosamine; (2) finished pharmaceutical preparations such as low-molecular-weight heparin injections, ambroxol, clemastine, metformin/glibenclamide, and gonadotropins; (3) nuclear medicine radiopharmaceuticals including 18F-FDG (≈50% China market share), technetium-based imaging agents, sodium fluoride F-18, iodine-125 seeds, and the proprietary Yunke Tc-99m MDP injection; and (4) consumer health products including the Jiabaolin supplement line and Kafukaka heparin-sodium-based skincare line, distributed through pharmaceutical wholesalers, hospital procurement, and e-commerce channels to over 40 countries.

Product overview

Yantai Dongcheng Pharmaceutical (烟台东诚药业集团股份有限公司) is a large pharmaceutical group listed on the Shenzhen Stock Exchange (stock code: 002675), founded in 1998. The company operates four business segments: Raw Material Medicine (原料药业务板块), Preparation (制剂业务板块), Nuclear Medicine (核药业务板块), and Health Care (大健康业务板块). The product portfolio encompasses four major categories: (1) Raw Material Medicines — heparin series (including heparin sodium API and low molecular weight heparin injections such as enoxaparin, nadroparin, and dalteparin), chondroitin sulfate series, cytochrome C, collagen, hyaluronic acid, and glucosamine; (2) Preparations — finished dosage forms including tablets, capsules, granules, drop pills, and injectable products covering respiratory, digestive, dermatological, and endocrine therapeutic areas; (3) Nuclear Medicine — radiopharmaceutical products including 18F-FDG (with ~50% domestic market share), technetium-based imaging agents, sodium fluoride injection, iodine-125 seeds, and carbon-14 urea capsules, distributed through 32 national nuclear medicine production centers; and (4) Health Care — dietary supplements (Jiabaolin glucosamine chondroitin, CoQ10, fish oil), cosmetics (Kafukaka heparin sodium skincare line), and functional foods. The company is anchored by key subsidiaries including Nanjing An Dikepo (nuclear medicine), Chengdu Yunke Pharmaceutical (Yunke rheumatoid arthritis drug), Shanghai Xinke Medicine (radioactive pharmaceuticals), and Mitu Biology (molecular imaging CRO).

Differentiator

Problem solved

Functional benefit

Brands

• 佳宝林 (Jiabaolin): Health supplement brand including 氨糖软骨素胶囊, 辅酶Q10软胶囊, 多种维生素矿物质片, 钙维生素D维生素K软胶囊, 鱼油软胶囊, 钙咀嚼片, 褪黑素片 - for joint health, cardiovascular support, and general wellness.
• 咔肤咔 (Kafuka)
• 云克 (Yunke)

Products and services

• Raw Material Medicine Series (原料药系列) Animal-derived active pharmaceutical ingredients including heparin sodium, chondroitin sulfate, cytochrome C, collagen, hyaluronic acid, and glucosamine APIs sold globally to pharmaceutical manufacturers and supplement producers.
• Finished Pharmaceutical Preparation Series (制剂药系列) Finished pharmaceutical dosage forms — tablets, capsules, granules, drop pills, lyophilized powder for injection, and small-volume injections in pre-filled syringes — covering therapeutic areas such as respiratory, allergy, dermatology, cardiovascular, and endocrinology, distributed through retail pharmacies and hospital procurement.
• Nuclear Medicine Series (核素药物系列) Radiopharmaceutical products for diagnostic imaging and therapeutic applications, including 18F-FDG injection, sodium fluoride [18F] injection, technetium-99m tetrofosmin injection, iodine-125 sealed seed sources, carbon-14 urea capsules, and the proprietary Yunke Tc-99m MDP injection. Distributed through a national network of 32 nuclear medicine production centers to hospital nuclear medicine departments and diagnostic imaging centers.
• Health Care Series (大健康系列) Consumer health products including the Jiabaolin dietary supplement line (glucosamine chondroitin capsules, multivitamins, CoQ10, fish oil, calcium chewable tablets, melatonin) and the Kafukaka cosmetics line (hand creams, hyaluronic acid masks, hydroxyproline masks, soothing serums) based on self-produced pharmaceutical-grade heparin sodium; sold through e-commerce platforms and retail pharmacy channels.
• Heparin Sodium API (肝素钠) Anticoagulant API extracted from porcine intestinal mucosa, used clinically for preventing thrombosis and embolism and as raw material for low molecular weight heparin drug production.
• Chondroitin Sulfate Series (硫酸软骨素系列) Sulfated glycosaminoglycan product line including sodium chondroitin sulfate, produced via extraction and microbial fermentation and exported to Europe and the United States for use in dietary supplements, pharmaceuticals, and animal feed.
• 18F-FDG Injection (氟[18F]脱氧葡糖注射液) Positron emission tomography (PET) radiopharmaceutical used for early tumor diagnosis, tumor staging, and treatment evaluation; holds approximately 50% of China's domestic market share.
• Yunke Injection (锝[99Tc]亚甲基二膦酸盐注射液) Proprietary radiopharmaceutical with independent Chinese intellectual property rights, indicated for rheumatoid arthritis and other autoimmune diseases as well as orthopedic conditions; developed by Chengdu Yunke Pharmaceutical and awarded National Key New Product certificate.
• Enoxaparin Sodium Injection (依诺肝素钠注射液) Low molecular weight heparin injection for prevention of venous thromboembolism, treatment of deep vein thrombosis, unstable angina and non-Q-wave myocardial infarction, and extracorporeal circulation anticoagulation during hemodialysis.
• Iodine-125 Sealed Seed Source (碘[125I]密封籽源) Brachytherapy implant for interstitial radiation treatment of various malignant tumors, produced by Shanghai Xinke Pharmaceutical.
• Carbon-14 Urea Capsule (碳[14C]尿素胶囊) Diagnostic agent for Helicobacter pylori detection, suitable for large-scale screening and epidemiological studies; produced by Shanghai Xinke Pharmaceutical.
• Ambroxol Hydrochloride Dispersible Tablets (盐酸氨溴索分散片) Respiratory mucolytic product for expectorant therapy, listed on China's national essential drug list and national medical insurance catalog, and passed generic drug consistency evaluation.
• Jiabaolin Glucosamine Chondroitin Capsule (佳宝林牌氨糖软骨素胶囊) Joint health dietary supplement using a 3.0 formula combining glucosamine, chondroitin, and collagen to provide comprehensive joint care; flagship product of Yantai Dongcheng Dingrui Health Industry.
• Kafukaka Skincare Series (咔肤咔化妆品系列) Cosmetics brand based on self-produced heparin sodium, featuring five hand cream variants, hydroxyproline masks, hyaluronic acid masks, and soothing moisturizing serums; positioned for gentle skin care.

Quantifiable outcome

• 18F-FDG holds approximately 50% domestic market share in China's PET radiopharmaceutical market
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered minor and core.

• Global Pharmaceutical Industry at CPHI China 2026minorChannel Partner/ Reseller/ Distributor · 1 June 2026Participated in CPHI China 2026 exhibition with 3700+ exhibitors, conducting business discussions with existing and potential international customers for API products
• Yantai Huang Bohai New Area Working Committee OfficeminorGTM or Marketing Partner · 1 January 2020Collaborative poverty assistance program donating to Chaoshui Second Village for three consecutive years, supporting rural revitalization initiatives
• East China University of Science and Technology (华东理工大学)coreStrategic or Co-development Partner · 1 January 2018Acquired Nanjing Jiangyuan Andike Nuclear Electronics in 2018, integrating nuclear medicine expertise with university research capabilities for radiopharmaceutical development
• China Nuclear Power Research and Design Institute (中国核动力研究设计院)coreStrategic or Co-development Partner · 1 January 1992Chengdu Yunke originated from China Nuclear Power Research and Design Institute's isotope application technology research institute, maintaining ongoing collaboration for radiopharmaceutical R&D and talent development

Scale indicators13 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• PETNET Solutions (Siemens Healthineers): Operates one of the largest networks of PET radiopharmaceutical production centers globally; directly comparable to Dongcheng's 32-center Chinese PET distribution network from a strategic-network perspective.
• GE HealthCare: Large diversified medical imaging and radiopharma incumbent that competes with Dongcheng on PET tracer production, while also offering MRI, CT, and broader imaging contrast agents.
• China Grand Pharmaceutical and Healthcare Holdings: Hong Kong-listed diversified Chinese specialty pharma group with API, finished formulations, and nuclear medicine interests; comparable as a publicly traded broad-pharma peer with similar regulatory coverage.

Direct peers

• Lantheus Holdings: US-based diagnostic radiopharmaceutical specialist with a focus on PET and SPECT agents; comparable in product class to Dongcheng's nuclear medicine portfolio despite different geography.
• Bioiberica: Spanish manufacturer of chondroitin sulfate and heparin-derived APIs for pharmaceutical, nutraceutical, and animal-health uses; competes with Dongcheng's chondroitin franchise globally.
• Curium Pharma: Global nuclear medicine company producing diagnostic and therapeutic radiopharmaceuticals; comparable as a vertically integrated radiopharma network player competing for similar contract manufacturing and supply roles.
• Sinotau Pharmaceutical Group: China's most prominent domestic competitor in PET radiopharmaceuticals; directly competes with Dongcheng's 18F-FDG and other diagnostic tracers for hospital nuclear medicine contracts.
• Shenzhen Hepalink Pharmaceutical Group: Leading Chinese heparin sodium API producer and one of the largest in the world, directly competing with Dongcheng in low molecular weight heparin and crude heparin supply chains globally.
• Hebei Changshan Biochemical Pharmaceutical: Major Chinese heparin and chondroitin sulfate manufacturer with overlapping API and finished LMWH product lines targeting both domestic and international customers.

Emerging players

• Telix Pharmaceuticals: Australian-headquartered radiopharma company focused on diagnostic and therapeutic radiopharmaceuticals; converges with Dongcheng's pipeline direction (theranostics) though at an earlier commercialization stage and with Western market focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights8 records

Customer concentration

Compliance12 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments4 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Yantai Dongcheng Pharmaceutical